Effect of prediabetes on tuberculosis treatment outcomes: A study from South India

Diabetes Metab Syndr. 2023 Jul;17(7):102801. doi: 10.1016/j.dsx.2023.102801. Epub 2023 Jun 8.

Abstract

Background and aims: The aim was to assess the effect of prediabetes on tuberculosis(TB) treatment outcomes.

Methods: This is a prospective observational cohort study of 569 eligible new smear positive cases screened for DM between 2014 and 2018 in TB units in North Chennai, South India. Based on study criteria, a total of 187 subjects were included and categorised into two groups: TB with normoglycaemia (groupI) (HbA1c<5.7%) and TB with prediabetes (group II) (HbA1c = 5.7-6.4%) and followed them at 3rd and 6th month and treatment outcomes were assessed at the end of the TB treatment.

Results: Total cure rate was 72.7% with no significant difference between the groups. Higher proportion of deaths occurred in group II (6.3%) compared to group I (1.3%) (p = 0.09). At the end of intensive phase of directly observed therapy (DOTS) treatment, about 23.8% were observed to have positive sputum smear in group II compared to 8.6% in group I(p = 0.019). The estimated relative risk to remain as sputum smear positive among people with prediabetes at the end of intensive phase was 3.0(95% CI: 1.2-7.6). There was a significant association found with HbA1c at enrollment and unfavourable TB treatment outcomes (β = 1.38, [odds ratio (95% CI) 3.98(1.65-9.64); p = 0.007].

Conclusion: Death rate was high and there was a delay in sputum conversion among TB patients with prediabetes at the end of the intensive phase of TB treatment. HbA1c at the time of diagnosis of prediabetes was significantly associated with unfavourable TB treatment outcomes.

Keywords: Prediabetes; South India; Treatment outcomes; Tuberculosis.

Publication types

  • Observational Study

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Cohort Studies
  • Glycated Hemoglobin
  • Humans
  • India / epidemiology
  • Prediabetic State* / drug therapy
  • Prediabetic State* / epidemiology
  • Tuberculosis* / complications
  • Tuberculosis* / drug therapy
  • Tuberculosis* / epidemiology
  • Tuberculosis, Pulmonary*

Substances

  • Antitubercular Agents
  • Glycated Hemoglobin